Display options
Cite
Osman AM, Al-Harthi SE, AlArabi OM, et al. Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int. 2013;13:52doi: 10.1186/1475-2867-13-52.
Osman, A. M., Al-Harthi, S. E., AlArabi, O. M., Elshal, M. F., Ramadan, W. S., Alaama, M. N., Al-Kreathy, H. M., Damanhouri, Z. A., & Osman, O. H. (2013). Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer cell international, 1352. https://doi.org/10.1186/1475-2867-13-52
Osman, Abdel-Moneim M, et al. "Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals." Cancer cell international vol. 13 (2013): 52. doi: https://doi.org/10.1186/1475-2867-13-52
Osman AM, Al-Harthi SE, AlArabi OM, Elshal MF, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA, Osman OH. Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int. 2013 May 28;13:52. doi: 10.1186/1475-2867-13-52. eCollection 2013. PMID: 23714221; PMCID: PMC3680308.
Copy Download .nbib Format: NLM
Share it on

Cancer Cell Int. 2013 May 28;13:52. doi: 10.1186/1475-2867-13-52. eCollection 2013.

Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals.

Cancer cell international

Abdel-Moneim M Osman, Sameer E Al-Harthi, Ohoud M AlArabi, Mohamed F Elshal, Wafaa S Ramadan, Mohamed N Alaama, Huda M Al-Kreathy, Zoheir A Damanhouri, Osman H Osman

Affiliations

  1. Pharmacology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia ; National Cancer Institute, Cairo University, Cairo, Egypt.
  2. Pharmacology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia ; Princess Al-Jawhara Center of Excellence in Research of Hereditary Disorders, Jeddah, Saudi Arabia.
  3. Pharmacology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  4. Princess Al-Jawhara Center of Excellence in Research of Hereditary Disorders, Jeddah, Saudi Arabia ; Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
  5. Molecular biology Department, Genetic engineering and Biotechniology Department, Minoufia University, Minoufia, Egypt ; Department of Anatomy, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  6. Department of Medicine, Cardiology unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

PMID: 23714221 PMCID: PMC3680308 DOI: 10.1186/1475-2867-13-52

Abstract

BACKGROUND: Doxorubicin (DOX), an anthracycline antibiotic is one of the most effective anticancer drug used in the treatment of variety of cancers .Its use is limited by its cardiotoxicity. The present study was designed to assess the role of a natural product resveratrol (RSVL) on sensitization of mammary carcinoma (Ehrlich ascites carcinoma) to the action of DOX and at the same time its protective effect against DOX-induced cardiotoxicity in rats.

METHODS: Ehrlich ascites carcinoma bearing mice were used in this study. Percent survival of tumor bearing mice was used for determination of the Cytotoxic activity of DOX in presence and absence of RSVL. Uptake and cell cycle effect of DOX in tumor cells in the presence of RSVL was also determined. Histopatholgical examination of heart tissues after DOX and/or RSVL therapy was also investigated.

RESULTS: DOX at a dose level of 15 mg/kg increased the mean survival time of tumor bearing mice to 21 days compared with 15 days for non tumor-bearing control mice. Administration of RSVL at a dose level of 10 mg/kg simultaneously with DOX increased the mean survival time to 30 days with 70% survival of the tumor-bearing animals. RSVL increased the intracellular level of DOX and there was a strong correlation between the high cellular level of DOX and its cytotoxic activity. Moreover, RSVL treatment showed 4.8 fold inhibition in proliferation index of cells treated with DOX. Histopathological analysis of rat heart tissue after a single dose of DOX (20 mg/kg) showed myocytolysis with congestion of blood vessels, cytoplasmic vacuolization and fragmentation. Concomitant treatment with RSVL, fragmentation of the muscle fiber revealed normal muscle fiber.

CONCLUSION: This study suggests that RSVL could increase the cytotoxic activity of DOX and at the same time protect against its cardiotoxicity.

Keywords: Cardioprotection; Cell cycle disturbance; Doxorubicin; Potentiation; Resveratrol

References

  1. Cancer. 1973 Aug;32(2):302-14 - PubMed
  2. Cell Prolif. 2011 Dec;44(6):591-601 - PubMed
  3. Free Radic Biol Med. 2009 Jun 15;46(12):1589-97 - PubMed
  4. Biochem Pharmacol. 2002 Nov 1;64(9):1375-86 - PubMed
  5. J Clin Oncol. 2008 Aug 1;26(22):3777-84 - PubMed
  6. Food Chem Toxicol. 2009 Oct;47(10):2425-30 - PubMed
  7. Food Chem Toxicol. 2010 Mar;48(3):951-6 - PubMed
  8. Chemotherapy. 1991;37(1):57-61 - PubMed
  9. Mol Cancer Ther. 2005 Apr;4(4):554-61 - PubMed
  10. N Engl J Med. 1998 Sep 24;339(13):900-5 - PubMed
  11. Cancer Lett. 2009 Oct 18;284(1):1-6 - PubMed
  12. Biochem Biophys Res Commun. 1998 Sep 8;250(1):53-8 - PubMed
  13. Cancer Cell Int. 2012 Nov 16;12(1):47 - PubMed
  14. Surgery. 2004 Jul;136(1):57-66 - PubMed
  15. Carcinogenesis. 2001 Aug;22(8):1111-7 - PubMed
  16. Curr Med Chem Anticancer Agents. 2003 Mar;3(2):77-93 - PubMed
  17. Carcinogenesis. 1999 Feb;20(2):237-42 - PubMed
  18. J Cell Physiol. 1983 Sep;116(3):397-403 - PubMed
  19. Nitric Oxide. 2012 Feb 15;26(2):102-10 - PubMed
  20. Int J Surg. 2010;8(6):448-52 - PubMed
  21. Clin Cancer Res. 2002 Mar;8(3):893-903 - PubMed
  22. J Pharm Pharmacol. 2004 Aug;56(8):1001-5 - PubMed
  23. Chemotherapy. 1995 Sep-Oct;41(5):368-77 - PubMed
  24. Free Radic Res. 2009 Mar;43(3):195-205 - PubMed
  25. Anticancer Res. 2004 Sep-Oct;24(5A):2783-840 - PubMed

Publication Types